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Presently, co-culture of human umbilical cord blood mesenchymal stem cells (hUCB-MSCs) with BV2 microglia under amyloid-
b42 (Ab42) exposure induced a reduction of Ab42 in the medium as well as an overexpression of the Ab-degrading enzyme
neprilysin(NEP)inmicroglia.Cytokinearrayexaminationsofco-culturedmediarevealedelevatedreleaseofsolubleintracellular
adhesion molecule-1 (sICAM-1) from hUCB-MSCs. Administration of human recombinant ICAM-1 in BV2 cells and wild-type mice
brains induced NEP expression in time- and dose-dependent manners. In co-culturing with BV2 cells under Ab42 exposure,
knockdown of ICAM-1 expression on hUCB-MSCs by small interfering RNA (siRNA) abolished the induction of NEP in BV2 cells
as well as reduction of added Ab42 in the co-cultured media. By contrast, siRNA-mediated inhibition of the sICAM-1 receptor,
lymphocyte function-associated antigen-1 (LFA-1), on BV2 cells reduced NEP expression by ICAM-1 exposure. When hUCB-
MSCs were transplanted into the hippocampus of a 10-month-old transgenic mouse model of Alzheimer’s disease for 10, 20, or
40 days, NEP expression was increased in the mice brains. Moreover, Ab42 plaques in the hippocampus and other regions were
decreased by active migration of hUCB-MSCs toward Ab deposits. These data suggest that hUCB-MSC-derived sICAM-1
decreases Ab plaques by inducing NEP expression in microglia through the sICAM-1/LFA-1 signaling pathway.
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Alzheimer’s disease (AD) is an irreversible neurodegenera-
tive disease that is accompanied by amyloid-b (Ab) accumu-
lation, tau aggregation, and chronic inﬂammation.
1 Clinical
trials evaluating new drugs for AD patients have proved
disappointing. For example, phase-III clinical trials of
Dimebon, a spotlighted candidate drug for AD, failed.
2
Therefore, the limitations of conventional drugs call for a
paradigm shift in AD research.
In this light, stem cell therapeutics for incurable diseases is
relevant.Stemcellshavetheabilitytoself-renewanddifferentiate
intotissues.
3Althoughhumanumbilicalcordbloodmesenchymal
stem cells (hUCB-MSCs) are allogeneic stem cells, their
transplantation does not induce immunological problems in hosts
because these cells do not express major histocompatibility
complex class-II molecules and T-cell co-stimulatory factors.
4–6
In addition, collection of hUCB-MSCs is less invasive and they
are easily obtained from cord blood after birth.
Recently, many groups have reported that stem cells have
regenerative as well as paracrine effects. The paracrine roles
of stem cells have been shown in that stem cell-derived
soluble factors can modulate apoptosis, differentiation, pro-
liferation, and inﬂammation in damaged tissue.
7–9 In particu-
lar, our group has shown that galectin-3, which is secreted by
hUCB-MSCs, reduces Ab neurotoxicity in rat primary neu-
rons.
10 Furthermore, our group reported that transplantation
of hUCB-MSCs improved spatial memory deﬁcits and
reduced Ab deposits in a transgenic mouse model of
AD.
11,12AlthoughtoxicAbdepositswerereducedsigniﬁcantly
in the hUCB-MSC-transplanted mice, the molecular mechan-
isms are poorly understood.
The present study sought to clarify the mechanisms
involved. Transplantation of hUCB-MSCs in AD transgenic
mice induced the expression of the Ab-degrading enzyme
neprilysin (NEP) in microglia through a paracrine mechanism.
Analysis of the proteins secreted by hUCB-MSCs revealed
that soluble intracellular adhesion molecule-1 (sICAM-1) is
released from hUCB-MSCs, which, in turn, induces NEP in
microglia for Ab clearance.
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Co-culture of hUCB-MSCs induces NEP expression in
microglia. As transplantation of hUCB-MSCs reduces Ab
deposits in vivo,
11,12 we tested whether co-culture with
hUCB-MSCs in a Transwell chamber could affect the
expression of Ab metabolic enzymes, including NEP, in rat
primary neuronal cultures. NEP is an Ab-degrading enzyme
that is emerging as a therapeutic target in AD.
13 After co-
culture with hUCB-MSCs for 24h in the presence or absence
of 10mMA b42, NEP expression in rat primary neuronal
cultures was analyzed by reverse transcription-PCR
(RT-PCR) and western blot analysis (Figure 1). Co-culture
with hUCB-MSCs induced NEP expression in cultured rat
primary neuronal culture in the absence and presence of
Ab42 (Figure 1a). As the rat primary neuronal cultures
contained a mixture of neuronal and glial cells, we performed
a colocalization analysis of NEP-positive cells and microglia
(Figure 1b), and neurons (Supplementary Figure S1a). Co-
culture with hUCB-MSCs in the presence of Ab42
demonstrated colocalization of microglia and NEP-
expressing cells (red color) by double staining using
Figure1 Co-culturewithhUCB-MSCsinducesNEPexpressioninmicroglia.(a)Ratprimaryneuronalcultureswerepreparedfrom14-day-oldembryonicratsasdescribed
under Materials and Methods. Rat primary neuronal cultures (in the lower chamber of a Transwell unit) were co-cultured with hUCB-MSCs (in the upper chamber of the
Transwell unit) in the presence or absence of 10mMA b42 for 24h. To examine the levels of mRNA and protein expression of NEP in rat primary cultures, protein extracts or
totalRNAwereanalyzedbywesternblotanalysisorRT-PCR,respectively.(b)ToexamineNEP-expressingcellsinratprimarycultures,whichcontainedamixtureofneuronal
andglialcells,ratprimaryculturesco-culturedwith hUCB-MSCs wereco-stainedwith antibodiesagainstNEP(red)andthemicrogliamarkerCD11b(green).Colocalizationof
NEP-expressing cells and microglia was detected in a merged image. (c) To examine the reproducibility of induction of NEP expression by co-culturing with hUCB-MSCs,
hUCB-MSCs from six different donors were co-cultured with mouse microglial BV2 cells. The levels of NEP expression were analyzed by western blot analysis (densitometric
analysis, n¼6; *Po0.05). (d) To assess whether the increased NEP of BV2 cells induced by co-culturing with hUCB-MSCs degraded the added Ab42 (10mM) in the co-
cultured media, the concentration of Ab42 in each medium was measured by ELISA in the presence and absence of siRNAs for NEP. BV2 cells were pretreated with NEP
siRNAs for 14h and these cells or only BV2 cells were then co-cultured with hUCB-MSCs in the presence of Ab42 for an additional 24h. The same amount of Ab42 (10mM)
was added in all conditions. (e) To conﬁrm knockdown of NEP expression in panel d, the above samples were analyzed by western blot analysis using an anti-human NEP
antibody. CONT indicates control siRNA
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Cell Death and Differentiationantibodies against CD11b, a marker of microglia (green), and
NEP (Figure 1b). Although staining in some microtubule-
associated protein-2 (MAP2)-positive cells (neurons) merged
with NEP-expressing cells, the majority of NEP-positive cells
were microglia. Moreover, we tested upregulation of NEP in
mouse microglial BV2 cells by co-culturing them with hUCB-
MSCs isolated from six different donors. Western blot
analysis revealed that co-culture of six hUCB-MSCs
induced an upregulation of NEP in BV2 cells (*Po0.05
versus BV2 cells only; Figure 1c). As co-culture with hUCB-
MSCs induced NEP expression in BV2 cells, we measured
the concentration of added Ab42 in the co-cultured media to
determine whether endogenous NEP was induced in
microglia or whether neurons degraded Ab42 in the media.
The level of Ab42 in the media was compared when hUCB-
MSCs were co-cultured with BV2 cells or human neuro-
blastoma SH-SY5Y cells (Supplementary Figure S1b).
Signiﬁcant reductions in Ab42 concentration were observed
in the media of BV2 cells co-cultured with hUCB-MSCs in the
presence of 10mMA b42, as compared with the media of SH-
SY5Y co-cultured with the same concentration of Ab42
(*Po0.05 versus SH-SY5Y alone with Ab42 (n¼3 per
group); and **Po0.05 versus BV2 alone with Ab42 (n¼3
per group)). These results may have been due to induction of
NEP in the majority of microglia. To determine whether
reduction of Ab42 in the media was mediated by NEP in
microglia, two different small interfering RNAs (siRNAs) for
NEP were transfected into BV2 cells, which were then co-
cultured with hUCB-MSCs in the presence of 10mMA b42.
The concentration of added Ab42 was reduced signiﬁcantly
in the media of BV2 cells co-cultured with hUCB-MSCs or
control siRNA-treated hUCB-MSCs, as compared with BV2
cells cultured alone in the same amount of Ab42. By contrast,
pretreatment of BV2 cells with two different NEP siRNAs
abolished this reduction of Ab42 in the media upon co-culture
with hUCB-MSCs (Figure 1d). The effect of NEP knockdown
was evaluated by western blot analysis (Figure 1e). The data
indicate that hUCB-MSCs reduced Ab42 through induction of
NEP expression in microglia.
Identiﬁcation of sICAM-1 as a paracrine factor released
by hUCB-MSCs for NEP induction. In Transwell chamber
experiments, cells cannot pass through the Transwell
membrane because of the restrictive pore size (1mm).
Thus, secreted factors released from hUCB-MSCs can act
on microglia in the co-culture system. To identify the
paracrine factors, cytokine array were performed by using
the following conditioned media: hUCB-MSCs or BV2 cells
alone; Ab42-treated hUCB-MSCs or BV2 cells; and BV2 cells
co-cultured with hUCB-MSCs in the presence or absence of
Ab42 (Figure 2a). Densitometric analysis revealed that
interleukin-8 (IL-8), IL-6, growth-regulated oncogene-a
(GRO-a), and ICAM-1 cytokines were markedly increased
in the media of BV2 cells co-cultured with hUCB-MSCs in
both the presence and in the absence of Ab42 (Figure 2b,
n¼3 per group; *Po0.05 versus MSC alone). Next, we
examined which co-cultured cells secreted the identiﬁed
cytokines. After co-culturing BV2 cells with hUCB-MSCs,
either cell type was harvested separately and the expression
of each individual cytokine was analyzed by RT-PCR. IL-8,
IL-6, GRO-a, and ICAM-1 were overexpressed in co-cultured
hUCB-MSCs but not in BV2 cells (Figures 2c and d). In
particular, ICAM-1 levels were increased by co-culturing BV2
cells with hUCB-MSCs obtained from two individuals
(Figure 2d). These data demonstrate that increased levels
of ICAM-1 were released from hUCB-MSCs by co-culturing
with BV2 cells.
Amongthesecytokines,onlyICAM-1treatmentinducedthe
expression of NEP in BV2 cells in time- and dose-dependent
manners (Figure 3a, *Po0.05 versus without recombinant
ICAM-1; n¼3 per group). As NEP expression was upregu-
lated by ICAM-1 in the absence and presence of Ab42
(Figure 3a), a dose of 500 or 1000ng/kg of human
Figure 2 Cytokine analyses identify four proteins that are upregulated in the
media of BV2 cells co-cultured with hUCB-MSCs. (a) Medium was collected from
BV2 cells and hUCB-MSCs alone; BV2 cells co-cultured with hUCB-MSCs in the
presence and absence of Ab42; and BV2 cells or hUCB-MSCs alone in the
presence of Ab42. Cytokine analysis was performed according to a recommended
protocol. The boxed area indicates upregulationof four proteins in the mediumfrom
BV2 cells co-cultured with hUCB-MSCs in the presence or absence of Ab42. (b)A
typical result of densitometric analysis obtained from three independent
experiments (n¼3 per group; *Po0.05 versus MSC alone). (c) To determine
which cells secreted GRO-a, IL-6, IL-8, and ICAM-1 when co-cultured in the
Transwell system, BV2 cells and hUCB-MSCs were co-cultured and then analyzed
byRT-PCRusingaspeciﬁcprimerforhumanGRO-a,IL-6,andIL-8.(d)Inthesame
experimentasinpanelc,BV2cellswereco-culturedwith twodifferenthUCB-MSCs
to analyze ICAM-1 expression in RT-PCR using a primer for human ICAM-1
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Cell Death and Differentiationrecombinant ICAM-1 or phosphate-buffered saline (PBS) was
administered to the hippocampus of 10-month-old littermate
micefor7 days. After 7 days, thebrain tissue was analyzed by
western blot analysis to determine the levels of NEP
expression. NEP levels were upregulated in the 1000ng/kg
ICAM-1-injected groups (Figure 3b, *Po0.05 versus PBS
control; n¼4 each group). In addition, pretreatment of hUCB-
MSCs with two different ICAM-1 siRNAs reduced the levels of
secreted sICAM-1, as well as overexpression of NEP, in BV2
cells co-cultured with hUCB-MSCs (Figures 3c and d). To
examine knockdown of sICAM-1 in hUCB-MSCs, medium was
collected and ICAM-1 levels were analyzed by ELISA (Figure 3c,
*Po0.05 versus the control siRNA-treated group; n¼3 per
group). Consequently, knockdown of ICAM-1 in hUCB-MSCs
reduced the degradation of Ab42 (Figure 3e), as well as NEP
expression (Figure 3d), in the BV2 cells in the co-culture system
(*Po0.05 versus the control siRNA-treated group; n¼3 per
group). These data indicate that sICAM-1 derived from hUCB-
MSCs induced the expression of NEP in microglia and a
reduction in Ab42 levels.
Figure 3 Identiﬁcation of hUCB-MSC-derived sICAM-1 as an inducer of NEP expression in microglia. (a) BV2 cells were treated with human recombinant ICAM-1 in a
dose-(5,10,and50ng/ml)andtime-dependent(12,24,36,or48h)manner.Eachcelllysatewasanalyzedwithananti-NEPantibodybywesternblotanalyses.Densitometric
analyses indicated an increase of NEP in three independent experiments (*Po0.05). (b) Dose-dependent human recombinant ICAM-1 (500 and 1000ng/kg) was injected
bilaterallyintothehippocampusofB6C3micefor7days.Ascontrol,PBSwasinjectedintobothhippocampi.Thecollectedbrainswereanalyzedbywesternblotanalysisusing
an anti-NEP antibody. NEP levels were upregulated at 1000ng/kg when analyzed by densitometric analysis (n¼4 per group; *Po0.05 versus PBS control). (c) To knock
down ICAM-1 in hUCB-MSCs, hUCB-MSCs were pretreated with an siRNA control (siCONT) or siRNA (A) and siRNA (B) of ICAM-1 for 14h, and then these cells were co-
cultured with BV2 cells for an additional 24h in the presence of Ab42. The levels of sICAM-1 in each media were measured by ELISA (*Po0.05; n¼3 per group). (d) BV2
cells were harvested from the above conditions and analyzed by western blot analysis using an anti-NEP antibody. (e) To determine whether the reduced sICAM-1 secretion
affected the ability of Ab42 reduction by hUCB-MSCs, the Ab42 levels in the media were measured by Ab42 ELISA. (f) To knock down LFA-1, BV2 cells were pretreated for
14h with two different siRNAs for LFA-1, siRNA LFA-1 A and LFA-1 B, and then these cells were exposed to recombinant ICAM-1 (20ng/ml) for 24h. Knockdown of LFA-1
wasconﬁrmedbyRT-PCR.ReducedNEPexpression bysiRNAsof LFA-1was conﬁrmedbywesternblotanalysisusingan anti-NEPantibody.DensitometricanalysisofNEP
was performed in three independent experiments (*Po0.05; n¼3 versus siCONT-treated BV2 with ICAM-1)
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Cell Death and DifferentiationTo investigate the signal pathway of ICAM-1-induced NEP
expression on microglia, we tested whether ICAM-1 could
interact with its known receptor. As lymphocyte function-
associated antigen-1 (LFA-1), integrin-b2 has been proposed
as the ICAM-1 receptor in lymphocytes,
14,15 we tested
whether knockdown of LFA-1 expression in BV2 cells by two
different speciﬁc siRNAs of LFA-1 could abolish NEP
expression by ICAM-1 treatment. When LFA-1 expression
was reduced by these siRNAs, ICAM-1-induced NEP expres-
sion was also signiﬁcantly downregulated (Figure 3f). Knock-
down of LFA-1 on BV2 was conﬁrmed by RT-PCR and
immunostaining (Supplementary Figure S2). These data
indicated that ICAM-1-induced NEP expression could be
regulated by the integrin-b2 LFA-1-mediated signaling pathway.
Knockdown of ICAM-1 reduces the neuroprotective
effects of hUCB-MSCs against Ab42 neurotoxicity. To
determine the role of sICAM-1 in the neuroprotective effects
of hUCB-MSCs in Ab42-exposed rat primary neuronal
cultures, we compared the neuroprotective effects of
hUCB-MSCs in the absence and presence of two different
ICAM-1 siRNAs. Reduced levels of sICAM-1 in the media
were conﬁrmed by ELISA (Figure 4a). Reduction of Ab42
concentration was observed in rat primary neuronal cultures
after co-culturing with control siRNA-treated hUCB-MSCs, as
compared with co-culture with ICAM-1 siRNA-treated
hUCB-MSCs (Figure 4b) (*Po0.05 versus siRNA control
treated hUCB-MSC; n¼3 per group). Although hUCB-MSCs
alone protected Ab42-exposed, MAP2-positive rat primary
neurons, ICAM-1 siRNA-treated hUCB-MSCs did not protect
neurons from death (Figures 4c and d). The percentage of
surviving neurons was analyzed by counting the number of
MAP2-positive cells in each condition (n¼3 per group;
*Po0.05). These data indicate that the neuro-
protective effects of hUCB-MSCs were mediated by the
NEP expression induced by sICAM-1.
Transplantation of hUCB-MSCs induces NEP expression
in vivo. To evaluate the induction of NEP expression by
hUCB-MSCs in vivo, we performed bilateral transplantation
of hUCB-MSCs (2 10
4 cells per head) into the hippocampal
tissues of 10-month-old-APP/PS1 double-transgenic mice in
a time-dependent manner. As control, human skin ﬁbroblast
Hs68 cells were administered (Figure 5a). To check whether
injection was performed in accurate positions in the
hippocampus, brain tissues at 10 days were stained by a
human-speciﬁc anti-b2-microglobulin (brown). The majority
of transplanted hUCB-MSCs were stained in the needle track
of the hippocampus at 10 days (Figure 5b). Although these
antibodies detected human chondrocytes, they did not detect
Figure 4 Knockdown of ICAM-1 reduces the neuroprotective effects of hUCB-MSCs against Ab42 neurotoxicity. (a and b) As co-culturing with hUCB-MSCs protects rat
primary neuronal cell cultures from Ab42 neurotoxicity,
10 we evaluated the effects of ICAM-1 knockdown in hUCB-MSCs. After hUCB-MSCs were pretreated with siRNA (A)
and siRNA (B) for 14h, these hUCB-MSCs were co-cultured with rat primary neuronal cells. The levels of sICAM-1 and Ab42 were each conﬁrmed by ELISA. (c) Rat primary
neuronalcellsinthe lowerchamberwerethen stainedwith an anti-MAP2antibodyin orderto countthenumberof survivingneurons.(d) Neuroprotectionof hUCB-MSCswas
calculated by the percentage of the number of MAP2-positive neurons per number of DAPI-stained cells. Ct indicates cortical neuron. *Po0.05 versus control siRNA treated
MSC with Ab42
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Cell Death and Differentiationb2-microglobulin in mouse liver and muscle (Supplementary
Figure S3). To analyze the survival of transplanted hUCB-
MSCs, we double stained using an antibody for human-
speciﬁc anti-human nuclei (green) and human b2-micro-
globulin (red) at 10, 20, and 40 days. The stained hUCB-
MSCs were clearly detected, and the red and blue cells were
completely merged in images collected at 10 and 20 days.
However, hUCB-MSCs were signiﬁcantly reduced at 40 days
(Figure 5c) in all brain areas. Before transplantation of the
hUCB-MSCs, we examined the levels of NEP expression in
the transgenic mice at various ages. NEP expression was
signiﬁcantly reduced at 12 and 18 months (Figure 6a,
*Po0.05 versus 6-month-old transgenic mice; n¼4 per
group). However, Ab42 accumulation was noted. After
Figure 5 TransplantationofhUCB-MSCsinthebrainparenchymaofAPP/PS1transgenicmice.(a)hUCB-MSCs(2 10
4cellsperhead)orhumanskinﬁbroblasts,Hs68
(2 10
4 cells per head), were administered bilaterally into the hippocampus of 10-month-old APP/PS1 double-transgenic mice. Mice were Killed at 10, 20, and 40 days after
cell administration. (b) To detect transplanted hUCB-MSCs in mice brain, coronal sections of mice brain were co-stained using human-speciﬁc anti-b2-microglobulin and
hematoxylin. The magniﬁed box area indicates b2-microglobulin-positive hUCB-MSCs in the needle track. (c) To analyze the duration of survival of hUCB-MSCs in the brain,
each brain tissue at 10, 20, and 40 days was co-stained by using the two human-speciﬁc antibodies, anti-b2-microglobulin (red) and anti-human nuclei (green)
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Cell Death and Differentiationtransplantation of hUCB-MSCs and Hs68, mice were killed at
10, 20, and 40 days to perform western blot analyses and
immunohistochemistry (IHC). As in our in vitro data, NEP
expression was increased in a time-dependent manner by
transplantation of hUCB-MSCs as compared with the Hs68-
injected group (Figure 6b). In densitometric analysis, NEP
expression was signiﬁcantly increased by an average of 20%
and 38% at 20 and 40 days, respectively, after hUCB-MSC
transplantation, as compared with 10 days in the Hs68
controls (Figure 6b, *Po0.05; n¼4 per group). Another Ab-
degrading enzyme, insulin-degrading enzyme (IDE),
16 was
also applied to the same tissue. IDE expression levels were
not changed by hUCB-MSCs (Figure 6b).
ToanalyzethecolocalizationofmicrogliaandNEPexpression
in the hippocampal region of 20-day-old mice, double staining
was performed using antibodies against NEP and CD11b in
coronal brain sections (Figure 6c). It was difﬁcult to observe any
colocalization of microglia and NEP expression in the Hs68-
injected group (n¼4). However, NEP expression was clearly
noted in the microglia of the group transplanted with hUCB-
MSCs (n¼4). Colocalization of neurons and NEP expression
was also examined in tissues. A few MAP2-positive neurons
colocalized with NEP-expressing cells, as compared with
CD11b-positive microglia (Supplementary Figure S4). These
data indicate that transplanted hUCB-MSCs induced NEP
expression in the microglia of AD-transgenic mice.
Transplantation of hUCB-MSCs reduces Ab plaques
in vivo. To conﬁrm whether the number of Ab plaques
was affected by transplantation of hUCB-MSCs, thioﬂavin-S
Figure 6 Transplantation of hUCB-MSCs induces NEP expression in microglia in APP/PS1 mice. (a) Densitometric analyses (n¼4; *Po0.05) of western blot analyses
were performed to determine the levels of NEP expression and Ab42 accumulation in APP/PS1 mice at different ages (6, 9, 12, and 18 months). (b) After transplantation of
Hs68 and hUCB-MSCs (2 10
4 cells per head) at 10, 20, and 40 days in 10-month-old APP/PS1 mice, each brain tissue (not including the cerebellum) was analyzed by
western blot analysis using an anti-NEP antibody and an anti-IDE antibody. The band volume of NEP was analyzed by densitometry (n¼4; *Po0.05). (c) Coronal brain
sectionsfromanimalsat20daysweredouble-stainedusingCD11bandNEPantibodies.Thehippocampusregionwasexaminedbyconfocalmicroscopy.Thered/greencolor
shows CD11b-positive/NEP-positive cells. Two images were combined into a merged image
Reduction of Ab plaques by sICAM-1 of hUCB-MSC
J-Y Kim et al
686
Cell Death and Differentiationstaining of Ab plaques was performed in each of the
tested tissues from 40-day-old mice, although the majority
of hUCB-MSCs had disappeared (Figure 7A). The boxed
area in the images was magniﬁed to visualize Ab plaques
in each coronal section. Ab plaques in the hippocampal
(a and b) and cortical regions (c and d) from Hs68-injected
and hUCB-MSC-injected groups (Figure 7A) were magniﬁed.
Quantitative image analysis of the area occupied by the
Ab plaques showed statistically signiﬁcant reductions
(Figure 7B, *Po0.05; n¼4 per group) in hUCB-MSC-
transplanted mice, as compared with Hs68-injected
APP/PS1 mice. Additionally, reduced Ab42 monomers
were also conﬁrmed by western blot analysis using an
anti-Ab42 antibody (Figure 7C, *Po0.05 versus the
Hs68-injected group; n¼4 per group). Furthermore,
ELISA analyses of the same brain extracts revealed
Figure 7 Transplantation of hUCB-MSCs reduces Ab plaques in APP/PS1 mice. (A) Brain sections from the Hs68 and hUCB-MSC-injected groups that survived for 40
days were stained with thioﬂavin-S to visualize Ab plaques. The yellowish dots indicate Ab plaques. Images a and b indicate the enlarged hippocampal region, and images c
and d show the magniﬁed cortical region. (B)A b plaques were measured by image analysis (n¼4 per group; *Po0.05 versus the Hs68-injected group). (C) The levels of
Ab42weredetectedinbraintissues,includingthelittermate,theHs68-andhUCB-MSC-injectedgroups,bywesternblotanalysisusingananti-Ab42antibody.Litterindicates
littermate of APP-PS1 mice. Densitometric analysis revealed decreased Ab42 level in the hUCB-MSC-injected group (*Po0.05 versus the Hs68-injected group; n¼4).
Detergent-soluble andinsoluble Ab40 (D)o rA b42 (E) were analyzedby speciﬁcELISA(*Po0.05 versusthe Hs69-injectedgroup; n¼4 per group). Preparationof insoluble
and soluble Ab was performed as described by Nikolic et al.
29
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Cell Death and Differentiationthat the levels of both detergent-soluble and -insoluble Ab40
and Ab42 were reduced signiﬁcantly in the hUCB-MSC
injected groups (Figures 7D and E, *Po0.05; n¼4 per
group). As the results of thioﬂavin-S staining correlated
with western blot analysis using anti-Ab42 antibody
and ELISA, these data indicate that hUCB-MSC
transplantation decreased Ab plaques through NEP
expression of microglia.
Detection of hUCB-MSCs expressing ICAM-1 in other
brain areas. Although hUCB-MSCs were transplanted only
in the hippocampus, Ab plaques in remote cortices from the
hippocampus were reduced markedly (Figure 7). From this
phenomenon, we tested whether hUCB-MSCs could migrate
to other brain areas such as the cortex in the frontal lobe.
Brain tissues were collected from the frontal lobe of hUCB-
MSC-transplanted AD mice at 20 days and analyzed by
using anti-human nuclei (green) and ICAM-1 (red) antibodies
to analyze the colocalization of ICAM-1 and hUCB-MSC.
Interestingly, hUCB-MSCs expressing ICAM-1 were
detected in other brain areas at 20 days in AD mice
(Figures 8A–E). hUCB-MSCs expressing ICAM-1 (orange
cells in the merged image) were detected in the neocortex,
hypothalamus, amygdale, and striatum. Each region (a–e) is
marked in Figure 8F. In our previous reports,
17–19 hUCB-
MSC migrated toward the cell secreting the inﬂammatory
cytokine IL-8 in vitro and in vivo. Microglia that secrete
inﬂammatory cytokines are usually localized near Ab plaques
in AD.
20–22 Based on these ﬁndings, migrating hUCB-MSCs
(green) were often observed near Ab deposits (red) in brain
tissues (Figure 8G). This migration toward Ab plaques was
too robust, because hUCB-MSCs injected into the
cerebrospinal ﬂuid (CSF) through the cisterna magna also
migrated to the brain parenchyma. For example, under the
subarchoid space (yellow dashed line), part of the circulation
route of the CSF, migrating hUCB-MSCs were detected near
Ab deposits on the edge of cortex (box h in Figure 8F)
(Figure 8H). Surprisingly, when hUCB-MSCs were
inoculated in the hippocampus or the CSF in normal mice,
hUCB-MSC migration was not found in other brain areas
(data not shown). These data indicated that Ab plaques
located remotely from injection sites could be removed by
migration of hUCB-MSCs toward Ab deposits.
Discussion
Instemcelltherapy,severaltrialsusingADmodelshavebeen
conducted by using transplantation of rat or mouse neural
stem cells.
23–25 In these trials, Ab, IDE, and the tau status
were not altered by transplantation of neural stem cells. The
majority of these studies have demonstrated that transplanta-
tion of neural stem cells ameliorates AD-associated behavior-
al deﬁcits. Here, for the ﬁrst time, we demonstrate removal of
Ab through hUCB-MSC-derived sICAM-1 by induction of
endogenous NEP in a mouse model of AD.
The metabolism of Ab is a major target for new drug
development. In particular, NEP is an emerging target for
Ab-targeted drugs, because decreased Ab clearance in AD
patients was reported.
26 Therefore, recovery of NEP expression
in patients with AD may be a possible strategy for AD therapy.
In this study, expression of the Ab clearance enzyme, NEP,
was induced by co-culturing hUCB-MSCs in microglia cells.
NEP induced in the media was able to degrade Ab42 because
knockdown of NEP in BV cells abolished Ab removal by
hUCB-MSC co-culture (Figure 1). Moreover, transplantation
of hUCB-MSCs at 10, 20, and 40 days in the bilateral
hippocampusalsoinducedatime-dependentNEPexpression
in AD-transgenic mice (Figure 6). These data support the idea
that reduction of Ab plaques by hUCB-MSCs is due to
induction of NEP in mouse brain. In this study, we examined
how hUCB-MSCs can induce NEP in microglia by using a
Transwell system. From cytokine analyses of the conditioned
media, we identiﬁed release of ICAM-1 by hUCB-MSCs
(Figure 2) and found that recombinant ICAM-1 induced NEP
expression in vitro and in vivo (Figure 3). In addition,
knockdown of ICAM-1 expression in hUCB-MSCs abolished
the reduction of Ab42 and NEP expression in BV2 cells
(Figure 3). Consequently, the neuroprotective effects of
hUCB-MSCs were inhibited signiﬁcantly in rat primary
cultures with inhibition of ICAM-1 expression in hUCB-MSCs
(Figure 4). These data are consistent with the view that
sICAM-1 from hUCB-MSCs induces the expression of NEP in
microglia, which then remove Ab plaques (Figure 9).
ICAM-1 is a cell-surface molecule that is expressed by
multiple types of cells, including epithelial cells, leukocytes,
endothelial cells, and ﬁbroblasts. It is a member of the
immunoglobulin superfamily of adhesion molecules that are
involved in cell–cell and cell–matrix interactions. Although the
predominant function of ICAM-1 is cell adhesion, soluble and
circulating forms of ICAM-1 are detected in body ﬂuids,
including serum and the CSF.
27 Presently, ICAM-1 expres-
sion in naı ¨ve hUCB-MSCs was low because expression of
ICAM-1 mRNA or sICAM-1 in media was detected only in the
media of hUCB-MSCs co-cultured with BV2 cells (Figure 2).
LFA-1 is a receptor for ICAM-1 in lymphocytes.
14,15 We
conﬁrmed that knockdown of LFA-1 expression in BV2 cells
abolished ICAM-1-induced NEP expression in these cells
(Figure 3f). Especially, ICAM-1 stimulates downstream
extracellular signal-regulated kinase (Erk)-1,2 activation in
T-cell receptor activation through the LFA-1 signaling path-
way.
28 In this study, we examined several major kinases
during ICAM-1 exposure in BV2 cells. Among these, c-Jun
N-terminal kinase (JNK) and Erk-1,2 were activated in a time-
dependent manner. Inhibition of these two kinases by speciﬁc
inhibitors did not affect NEP expression by ICAM-1 in BV2
cells (data not shown). Although LFA-1/ICAM-1 interacts in
BV2 cells, such as occurs in lymphocytes, the downstream
signaling pathway should be investigated using phosphoki-
nase arrays to ﬁnd novel pathways. In conclusion, NEP
induction in microglia by ICAM-1 must be mediated by the
LFA-1, integrin-b2 pathway.
In this study, we observed an additional role of hUCB-MSC-
derived sICAM-1 in microglial function. In a previous report,
Nikolic et al.
29 reported that administration of hUCB-mono-
nuclear cells (MNCs) decreases Ab plaques by disrupting
CD40/CD40L activity in microglia. Interestingly, Tan et al.
reported that CD40 ligation promotes proinﬂammatory activa-
tion of microglia and reduces microglial phagocytosis of
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30 By contrast, interruption of CD40/CD40L
rescues Ab deposition and tau hyper-phosphorylation in an
AD animal model.
31 Based on these reports, we can conclude
that reduction of CD40 expression by hUCB-MNC adminis-
tration must be involved in a therapeutic effect in the AD
model. As reported previously, CD40 expression was
presently also downregulated by hUCB-MSC transplantation,
compared with the control groups (Supplementary Figure
S5a). Interestingly, we presently observed that exposure to
recombinantICAM-1reducedCD40expressioninBV2cellsin
Figure 8 Active migration of hUCB-MSCs expressing ICAM-1 in mice brain. In the hUCB-MSC-transplanted groups (20-day), the frontal lobe area of brain tissues was
co-stained by anti-human ICAM-1 (red), anti-human nuclei (green), and DAPI. (A–E) Regions from the neocortex, hypothalamus, amygdale, and striatum were observed
by confocal microscopy. (F) In the coronal section, each box indicates regions where migrated hUCB-MSCs were detected by using each antibody. (G) Region g in
panel F,A b deposits were stained by using an anti-amyloid antibody (red). To detect migrated hUCB-MSCs near Ab deposits, hUCM-MSCs were stained by using an
anti-human nuclei antibody. The white circles indicate Ab deposits in the brain. (H) hUCB-MSCs were transplanted through the cisterna magna for CSF circulation. After
20 days, the cortex tissue under the subarchoid space (yellow dashed line) was stained by using a human nuclei and Ab antibody
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this result, we propose that sICAM-1 may also be a soluble
factor to modulate CD40/CD40L activity.
As CD45, a tyrosine phosphatase (PTP), is a negative
regulator of CD40L-induced microglial activation.
32,33 To
determine CD45 expression in hUCB-MSC injected groups,
we also examined the expression of CD45 by western blot
analysis. Although there is no signiﬁcant difference in CD45
expression level between groups, we found a trend toward
slight increase (by 20%) in hUCB-MSC-transplanted mice as
compared with controls (Supplementary Figure S5a). How-
ever, BV2 cells exposed to recombinant ICAM-1 did not show
change of CD45 expression level (Supplementary Figure
S5b). Collectively, the data are consistent with the suggestion
that hUCB-MSC-derived sICAM-1 can improve microglia
functionforAb clearancethroughrecoveryofNEP expression
and disruption of CD40/CD40L activity.
Although hUCB-MSC was injected into only the hippocam-
pus,Abplaquesinotherareassuchastheremotecortexwere
also reduced (Figure 7). In our previous reports, hUCB-MSC
migration toward IL-8 was too strong, because the injected
hUCB-MSCs migrated toward the opposite hemispheres in
the glioma region of nude mice at 7 days. Moreover,
overexpression of the IL-8 receptor CXC chemokine recep-
tor-1 (CXCR1) on hUCB-MSCs enhances cell migration in
human glioma-bearing nude mice.
19 Detection of hUCB-
MSCs expressing ICAM-1 in other areas of the brain could be
due to active migration of hUCB-MSCs to Ab-exposed
microglia secreting inﬂammatory cytokines (Figure 8).
Based on our data, we received clearance last year from
the Korea Food and Drug Administration (KFDA) for a
phase-I clinical trial of AD (ClinicalTrials.gov Identiﬁer:
NCT01297218). We are now performing trials of administra-
tion of hUCB-MSCs in the brain parenchyma of AD patients.
We suggest that, after considering relevant ﬁndings in total,
hUCB-MSCs will constitute a new source of stem cell therapy
against Ab plaques in clinical trials.
Materials and Methods
PreparationofhUCB-MSCsandBV2cells. Thisstudywasapprovedby
the Institutional Review Board of MEDIPOST Co. Ltd. Umbilical cord blood was
collected from umbilical veins after neonatal delivery, with informed consent from
pregnant mothers. hUCB-MSCs were isolated and expanded according to the
procedure speciﬁed in a previous report.
10 To isolate and expand MSCs from cord
blood, MNCs were removed by using a Ficoll–Hypaque solution (d¼1.077g/cm
3;
Sigma-AldrichCo.,StLouis,MO,USA)andcellswerethenseededat5 10
5cells/
cm
2 in culture ﬂasks. After colonies of spindle-shaped cells formed, the cells were
reseeded for expansion. Hs68 cells (CRL-1635; ATCC, Rockville, MD, USA), which
were used as control, were cultured under identical culture conditions as the hUCB-
MSCs. hUCB-MSCs (8 10
4cells/cm
2) were co-cultured in the upper chamber of
a Transwell device (BD Biosciences, Franklin Lakes, NJ, USA) (pore size, 1mm)
with Ab42-exposed rat primary neuronal cells or BV2 cells. BV2 mouse microglia
cells were provided by Professor Inhee-Mook Jung (Seoul National University).
Rat primary neuronal cultures. All animal procedures were conducted in
accordance with institutional guidelines according to approved protocols. Pregnant
Sprague–Dawley rats were purchased from OrientBio Inc. (Kyeonggi, Korea). Brain
tissue was dissected from embryonic day 14 rat cortex and hippocampus, and cells
were mechanically dissociated in Ca
2þ/Mg
2þ-free Hank’s balanced salt solution.
Cells were allowed to proliferate in the presence of 20ng/ml basic ﬁbroblast growth
factor (bFGF) in serum-free neurobasal media. Cell proliferation was maintained in
bFGF for 4 days to reach 80% conﬂuence prior to induction of differentiation by
withdrawal of the mitogen. Rat primary neuronal cultures were treated with Ab42
(Sigma-Aldrich) for 12 or 24h. To induce neurotoxicity, Ab42 aggregation was
performed as described previously.
34 Brieﬂy, for the Ab42 oligomer, peptide was
ﬁrst resuspended in dimethylsulfoxide (Me2SO) to 5mM and then in cultured media
to achieve a ﬁnal peptide concentration of 100mM. Peptide suspensions were
incubated at 41C for 24h.
Western blot and ELISA. Cell extracts and tissues were prepared by
ultrasonication (Branson Ultrasonics Corporation, Danbury, CT, USA) in buffer
containing 9.8M urea, 4% CHAPS, 130mM dithiothreitol, 40mM Tris-HCl, and
0.1% sodium dodecyl sulfate (SDS). Protein amount was measured by Bradford
assay (Bio-Rad Laboratories, Hercules, CA, USA). Protein extract (20mg) was
separated by SDS-PAGE and the resolved proteins were transferred to
nitrocellulose membranes. In order to detect Ab42 in brain extracts, NuPAGE
12% Bis-Tris gels (Invitrogen, Carlsbad, CA, USA) were used to separate low-
molecular-weightproteinsbySDS-PAGE.Eachmembranewasincubatedwithanti-
NEP (R&D Systems, Minneapolis, MN, USA), anti-IDE (Calbiochem, San Diego,
CA, USA), and anti-Ab42 (Novus Biologicals, LLC, Littleton, CO, USA). ELISA was
performed according to the manufacturer’s instructions. An ICAM-1 ELISA kit (R&D
Systems) and kits for Ab40 or Ab42 (Wako Pure Chemical Industries Ltd, Osaka,
Japan) were used. For analysis of soluble and insoluble Ab40 and 42, brain tissues
were sonicated in ice-cold PBS containing 1% Triton X-100, 20mM Tris, 150mM
NaCl, 1mM EDTA, and a protease/phosphatase inhibitor cocktail. After centri-
fugation at 13000 r.p.m. for 15min at 41C, the supernatant was analyzed as a
soluble fraction and the pellet was resolubilized in 5M guanidine buffer.
29
IHC and thioﬂavin-S staining. For IHC of mouse brain, mice were killed
after hUCB-MSC transplantation. After transplantation, the animals immediately
underwent cardiac perfusion with 4% paraformaldehyde in PBS. After perfusion,
post-ﬁxation was performed overnight at 41C, and the brains were then incubated
againin30%sucroseat41Cuntiltheywereequilibrated.Sequential16-mmcoronal
cryosections were obtained on a CM1850UV cryostat microtome (Leica
Microsystems Inc., Jena, Germany) and stored at  201C. Tissues or cells were
stained with antibodies for MAP2 (Millipore, Billerica, MA, USA), tubulin-bIII
(Sigma-Aldrich), human nuclei (Millipore), human b2-microglobulin, Ab (Abcam,
Cambridge, MA, USA), or CD11b (AbD Serotec, Kidlington, UK). Fluorescein
isothiocyanate (FITC, Cy3)-labeled secondary antibodies (Jackson Immuno-
research Laboratories, Bar Harbor, MN, USA) or the VECTASTAIN Elite ABC Kit
(Vector Laboratories, Burlingame, CA, USA) were used and photographed using a
confocal microscope (Nikon Corporation, Tokyo, Japan). For thioﬂavin-S staining,
tissues were placed in 1% thioﬂavin-S solution (Sigma-Aldrich) and then
differentiated in 70% ethanol. Ab plaques were examined by quantitative image
analysis using the Metamorph 7.1.2 software (Molecular Devices, Sunnyvale,
CA, USA).
Figure 9 Therapeuticpotentialof hUCB-MSCsinAD.WhenhUCB-MSCsmeet
microglia, hUCB-MSCs secrete high levels of sICAM-1, which induces NEP
expression, a key Ab-degrading enzyme in microglia. Interestingly, hUCB-MSC-
derived sICAM-1 interrupted CD40/CD40L interaction on microglia through down
regulation of CD40 expression in microglia. Recently, we reported that galectin-3
that is secreted by hUCB-MSCs protects against Ab42 neurotoxicity.
10 Collectively,
hUCB-MSCs may participate simultaneously in Ab clearance and neuronal survival
through a paracrine mechanism in the AD microenvironment
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Cell Death and DifferentiationsiRNA treatment. siRNAs for NEP, LFA-1, and ICAM-1 were purchased from
Bioneer Corporation (Daejeon, Korea). BV2 cells and hUCB-MSCs were treated
with NEP siRNA and ICAM-1 siRNA, respectively, for 8–14h using the
Lipofectamine 2000 reagent (Invitrogen). These cells were cultured in complete
media overnight and co-cultured with hUCB-MSCs or BV2 cells.
Administration of hUCB-MSCs in mice. Double transgenic mice, Mo/Hu
APPswePS1dE9:APP/PS1werepurchasedfromJacksonLaboratory(BarHarbor,
ME, USA) and offsprig mice were produced, selected and maintained according to
the protocols recommended by Jackson Laboratory. Ten-month-old APP/PS1 mice
or their B6C3 littermates were anesthetized with ketamine/xylazine intraperitoneally
andﬁxedinastereotaxicapparatus(Stoelting,WoodDale,IL,USA)forhUCB-MSC
transplantation. Bilateral injections were performed by injecting 3ml of the cell
suspension(1 10
4cellsperhippocampus)orrecombinantICAM-1proteinintothe
dentategyrusofthehippocampus,or15mlofthesamenumberofcellsintocisterna
magna. hUCB-MSCs were stereotactically inoculated into the hippocampal area
(AP:  2.3, L: ±1.3, DV:  2.0 referenced to the bregma) or the cisterna magna
with a sterile Hamilton syringe ﬁtted with a 26-gauge needle (Hamilton Company,
Reno, NV, USA), using a microinfusion pump (KD Scientiﬁc, Holliston, MA, USA) in
a stereotaxic apparatus. The cell suspension was delivered at a rate of 0.5ml/min.
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